Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia.
Deisseroth
Albert
A
Farrell
Ann
A
Justice
Robert
R
Kane
Robert
R
Sridhara
Rajeshwari
R
Chen
Huanyu
H
He
Kun
K
Pazdur
Richard
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage / Q000009:adverse effects*; D007262:Infusions, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*
D000964:Antimetabolites, Antineoplastic; D006834:Hydrazines; D013449:Sulfonamides; D003561:Cytarabine; C483604:laromustine